Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Eye Disease

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44393   clinical trials with a EudraCT protocol, of which   7405   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    783 result(s) found for: Eye Disease. Displaying page 7 of 40.
    «« First « Previous 3  4  5  6  7  8  9  10  11  Next» Last»»
    EudraCT Number: 2010-024512-34 Sponsor Protocol Number: C-10-040 Start Date*: 2011-05-17
    Sponsor Name:Alcon Research, Ltd.
    Full Title: Safety and IOP-Lowering Efficacy of Brinzolamide 10 mg/ml / Brimonidine 2 mg/ml Fixed Combination Eye Drops, Suspension compared to Brinzolamide 10 mg/ml Eye Drops, Suspension and Brimonidine 2 mg/...
    Medical condition: Open-angle glaucoma and ocular hypertension
    Disease: Version SOC Term Classification Code Term Level
    14.1 100000004853 10030856 Open-angle glaucoma LLT
    14.1 100000004853 10020784 Hypertension ocular LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) PT (Completed) LV (Completed) DE (Completed) HU (Completed) LT (Completed) ES (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2019-003643-30 Sponsor Protocol Number: VGFTe-HD-DME-1934 Start Date*: 2020-06-03
    Sponsor Name:Regeneron Pharmaceuticals, Inc.
    Full Title: A Randomized, Double-Masked, Active-Controlled Phase 2/3 Study of the Efficacy and Safety of High-Dose Aflibercept in Patients with Diabetic Macular Edema
    Medical condition: Diabetic Macular Edema
    Disease: Version SOC Term Classification Code Term Level
    20.1 100000004853 10057934 Diabetic macular edema LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA) DE (Completed) HU (Completed) CZ (Completed)
    Trial results: View results
    EudraCT Number: 2018-000286-36 Sponsor Protocol Number: LEVODESA_04-2017 Start Date*: 2018-08-28
    Sponsor Name:NTC s.r.l.
    Full Title: An international, multicenter, randomized, blinded-assessor, parallel-group clinical study comparing eye drops of combined LEvofloxAcin + DExamethasone foR 7 days followed by dexamethasone alone fo...
    Medical condition: Prevention and treatment of inflammation and prevention of infection associated with cataract surgery
    Disease: Version SOC Term Classification Code Term Level
    20.0 10015919 - Eye disorders 10007739 Cataract PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2016-003361-25 Sponsor Protocol Number: SHP640-303 Start Date*: Information not available in EudraCT
    Sponsor Name:Shire Human Genetic Therapies, Inc.
    Full Title: A Phase 3, Multi-center, Randomized, Double-Masked Study to Evaluate the Clinical Efficacy and Safety of SHP640 (PVP-Iodine 0.6% and Dexamethasone 0.1%) Ophthalmic Suspension Compared to Placebo in...
    Medical condition: Bacterial Conjunctivitis
    Disease: Version SOC Term Classification Code Term Level
    20.0 10021881 - Infections and infestations 10061784 Conjunctivitis bacterial PT
    Population Age: Newborns, Infants and toddlers, Children, Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) EE (Completed) HU (Completed) ES (Completed) PL (Completed) AT (Completed) FR (Completed) GB (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2021-003380-95 Sponsor Protocol Number: CDYP688A12101 Start Date*: 2022-11-15
    Sponsor Name:Novartis Pharma AG
    Full Title: A Phase I/II, multi-center, open label study of DYP688 in patients with metastatic uveal melanoma (MUM) and other GNAQ/11 mutant melanomas
    Medical condition: MUM and other non-uveal, GNAQ/11 mutant melanomas
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10081431 Uveal melanoma PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10027481 Metastatic melanoma LLT
    20.0 100000004853 10030052 Ocular melanomas HLT
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Trial now transitioned) DE (Trial now transitioned) NL (Trial now transitioned) ES (Ongoing) NO (Ongoing) IT (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2011-004200-38 Sponsor Protocol Number: N11RFA Start Date*: 2012-03-28
    Sponsor Name:NKI-AVL
    Full Title: Phase II study exploring safety and efficacy of the combination of ipilimumab with radiofrequency ablation (RFA) in patients with unresectable uveal melanoma liver metastasis (SECIRA-UM)
    Medical condition: Unresectable uveal melanoma liver metastasis
    Disease: Version SOC Term Classification Code Term Level
    14.0 10015919 - Eye disorders 10030052 Ocular melanomas HLT
    14.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10027481 Metastatic melanoma LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2008-000580-41 Sponsor Protocol Number: LTG1030-PIV-12/07 Start Date*: 2008-04-02
    Sponsor Name:Laboratoires THEA
    Full Title: Safety and Efficacy assessment of Geltim LP ® 1 mg/g (unpreserved Timolol gel – TG1030) in ocular hypertensive or glaucomatous patients stabilized by Xalatan® with ocular intolerance signs
    Medical condition: The main objective is to assess the safety and the efficacy, in intra ocular pressure, of Geltim LP ® 1 mg/g (0.1% unpreserved timolol maleate gel) in glaucomatous patients initially treated and st...
    Disease: Version SOC Term Classification Code Term Level
    9.1 10018304 Glaucoma LLT
    9.1 10030043 Ocular hypertension LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2021-001970-41 Sponsor Protocol Number: 0504-19 Start Date*: 2022-03-18
    Sponsor Name:Intas Pharmaceuticals Ltd.
    Full Title: A Double Masked, Parallel Group, Randomized, Multicenter, Clinical Study to Compare Efficacy and Safety of Intas Ranibizumab with Lucentis® in Patients with Neovascular (Wet) Age-Related Macular De...
    Medical condition: Neovascular (Wet) Age-Related Macular Degeneration (AMD)
    Disease: Version SOC Term Classification Code Term Level
    27.0 10015919 - Eye disorders 10071129 Neovascular age-related macular degeneration PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: CZ (Completed) HU (Completed) PL (Completed) LV (Completed)
    Trial results: (No results available)
    EudraCT Number: 2010-022965-82 Sponsor Protocol Number: 201050 Start Date*: 2010-12-22
    Sponsor Name:Santen Oy
    Full Title: A phase III, randomized, double-masked 6-month clinical study to compare the efficacy and safety of the preservative-free fixed-dose combination of tafluprost 0.0015% and timolol 0.5% eye drops to ...
    Medical condition: Ocular hypertension and POAG, capsular glaucoma and pigmentary glaucoma
    Disease: Version SOC Term Classification Code Term Level
    14.1 10015919 - Eye disorders 10035015 Pigmentary glaucoma PT
    14.1 10015919 - Eye disorders 10030043 Ocular hypertension PT
    14.1 10015919 - Eye disorders 10036719 Primary open angle glaucoma LLT
    14.1 10015919 - Eye disorders 10037118 Pseudoexfoliation glaucoma LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FI (Completed) GB (Completed) DE (Completed) EE (Completed) NL (Completed) PL (Completed) IT (Completed) BE (Completed)
    Trial results: View results
    EudraCT Number: 2020-004836-93 Sponsor Protocol Number: 012603SA Start Date*: 2021-10-20
    Sponsor Name:SANTEN INCORPORATED
    Full Title: An Exploratory Study to Assess the 24-hour Intraocular Pressure (IOP) Lowering Characteristics, Duration of Action and Safety of DE-126 ophthalmic solution 0.002% versus Latanoprost ophthalmic solu...
    Medical condition: Primary Open-Angle Glaucoma (POAG) or Ocular Hypertension (OHT)
    Disease: Version SOC Term Classification Code Term Level
    20.0 10015919 - Eye disorders 10030043 Ocular hypertension PT
    20.0 10015919 - Eye disorders 10036719 Primary open angle glaucoma LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: DE (Completed) AT (Completed) GR (Completed)
    Trial results: View results
    EudraCT Number: 2018-003597-26 Sponsor Protocol Number: 1698-302-007 Start Date*: 2019-11-07
    Sponsor Name:Allergan Ltd.
    Full Title: An Extension Trial to Evaluate the Long-term Safety and Efficacy of Bimatoprost SR in Patients with Open Angle Glaucoma or Ocular Hypertension
    Medical condition: Open-angle Glaucoma and Ocular Hypertension
    Disease: Version SOC Term Classification Code Term Level
    20.0 10015919 - Eye disorders 10030043 Ocular hypertension PT
    20.0 10015919 - Eye disorders 10030856 Open-angle glaucoma LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA) DK (Completed) AT (Prematurely Ended) DE (Ongoing) BE (Completed) ES (Ongoing) IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2015-003079-31 Sponsor Protocol Number: QRK207 Start Date*: 2016-10-20
    Sponsor Name:Quark Pharmaceuticals Inc.
    Full Title: A PHASE 2/3, RANDOMIZED, DOUBLE-MASKED, SHAMCONTROLLED TRIAL OF QPI-1007 DELIVERED BY SINGLE OR MULTI-DOSE INTRAVITREAL INJECTION(S) TO SUBJECTS WITH ACUTE NONARTERITIC ANTERIOR ISCHEMIC OPTIC NEU...
    Medical condition: NAION typically presents as an abrupt, painless monocular vision loss. Visual loss varies widely, ranging from visual field loss only to complete blindness. The neuronal degeneration process in N...
    Disease: Version SOC Term Classification Code Term Level
    20.1 100000004853 10068242 Nonarteritic anterior ischaemic optic neuropathy LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) IT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2013-003272-12 Sponsor Protocol Number: SIVS1012 Start Date*: 2014-04-08
    Sponsor Name:Moorfields Eye Hospital
    Full Title: Clinical Efficacy and Mechanistic Evaluation of Aflibercept for Proliferative Diabetic Retinopathy
    Medical condition: Proliferative Diabetic Retinopathy (PDR)
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2007-000029-23 Sponsor Protocol Number: NVG06C103 Start Date*: 2008-10-16
    Sponsor Name:Novagali Pharma S.A.
    Full Title: A Phase III, Multicenter, Randomized, Controlled, Double-Masked Trial of NOVA22007 (Ciclosporin 0.1%) Ophthalmic Cationic Emulsion versus Vehicle in Patients with Moderate to Severe Dry Eye Syndrome
    Medical condition: Keratoconjunctivitis sicca (KCS), or dry eye syndrome
    Disease: Version SOC Term Classification Code Term Level
    9.1 10023350 Keratoconjunctivitis sicca PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: CZ (Completed) FR (Completed) ES (Completed) IT (Completed) DE (Completed) GB (Completed)
    Trial results: View results
    EudraCT Number: 2011-001078-25 Sponsor Protocol Number: H.34.04.04.07.B1 Start Date*: 2011-11-07
    Sponsor Name:National Institute of Health, National Eye Institute
    Full Title: Long-term Follow-up of Patients Who Participated in the Multicenter Uveitis Steroid Treatment Trial (MUST Trial Follow-up Study).
    Medical condition: Non-infectious pan, intermediate and posterior uveitis (inflammatory eye disease)
    Disease: Version SOC Term Classification Code Term Level
    14.0 10015919 - Eye disorders 10033687 Panuveitis LLT
    14.0 10015919 - Eye disorders 10046851 Uveitis PT
    14.0 10015919 - Eye disorders 10036370 Posterior uveitis LLT
    14.0 10015919 - Eye disorders 10022557 Intermediate uveitis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2010-018919-16 Sponsor Protocol Number: TG-MV-010 Start Date*: 2010-06-28
    Sponsor Name:ThromboGenics NV
    Full Title: An Open-Label, Ascending- Exposure-Time, Single Center Trial to Evaluate the Pharmacokinetic Properties of Ocriplasmin (Generic Name of the Molecule Microplasmin) Intravitreal Injection in Subjects...
    Medical condition: Patients who require primary pars plana vitrectomy. A sample of vitreous will be taken at beginning of surgery for PK analysis.
    Disease: Version SOC Term Classification Code Term Level
    12.1 10047644 Vitrectomy LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed)
    Trial results: View results
    EudraCT Number: 2005-000487-11 Sponsor Protocol Number: CRFB002D2201 Start Date*: 2005-09-30
    Sponsor Name:Novartis Pharma Service AG
    Full Title: A randomized, double-masked, multicenter, phase II study assessing the safety and efficacy of two concentrations of ranibizumab (intravitreal injections) compared with non-treatment control for the...
    Medical condition: Male and female patients >18 years of age with either type 1 or type 2 diabetes mellitus with stable HbA1c levels between 6.5 and 10% and diabetic macular edema with center involvement in at least ...
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) DK (Completed) GB (Completed) AT (Completed) ES (Completed) IT (Completed) PT (Completed)
    Trial results: View results
    EudraCT Number: 2013-000581-10 Sponsor Protocol Number: 12OY006 Start Date*: 2013-07-25
    Sponsor Name:Nottingham University NHS Trust
    Full Title: Evaluation of inflammatory markers in patients on topical anti-glaucoma drop therapy; a comparative trial of preserved and non-preserved primary medical treatment (eye drops) in patients with glauc...
    Medical condition: Glaucoma is the condition that is being treated by these eye drops - however the study is aimed at measuring the amount of inflammation that develops on the surface of the eye when these drops are ...
    Disease: Version SOC Term Classification Code Term Level
    14.1 10015919 - Eye disorders 10018307 Glaucoma and ocular hypertension HLGT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2019-000982-19 Sponsor Protocol Number: IOBA-ImmunEyez_011-2018 Start Date*: 2019-12-11
    Sponsor Name:Instituto de Oftalmobiología Aplicada (IOBA)
    Full Title: A Phase IV Open-Label Clinical Trial to Evaluate the Efficacy of Ikervis® on Clinical Parameters and Molecular/Cellular Biomarkers in Dry Eye Patients with Severe Keratitis who have not improved de...
    Medical condition: Dry eye disease with severe keratitis
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Completed)
    Trial results: (No results available)
    EudraCT Number: 2004-002245-12 Sponsor Protocol Number: EORTC 18021 Start Date*: 2005-01-27
    Sponsor Name:European Organisation for the Research and Treatment of Cancer
    Full Title: Intravenous versus intra-arterial fotemustine chemotherapy in patients with liver metastases from uveal melanoma: a randomized phase III study of the EORTC Melanoma Group.
    Medical condition: Uveal melanomas with specific hepatic tropism
    Disease: Version SOC Term Classification Code Term Level
    13.1 10015919 - Eye disorders 10030052 Ocular melanomas HLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Prematurely Ended) GB (Prematurely Ended) IT (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    «« First « Previous 3  4  5  6  7  8  9  10  11  Next» Last»»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Thu Apr 02 18:27:09 CEST 2026 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA